CN106421805B - A kind of dextran cross-linked haematoglobin carrier of oxygen and the preparation method and application thereof - Google Patents
A kind of dextran cross-linked haematoglobin carrier of oxygen and the preparation method and application thereof Download PDFInfo
- Publication number
- CN106421805B CN106421805B CN201610825741.2A CN201610825741A CN106421805B CN 106421805 B CN106421805 B CN 106421805B CN 201610825741 A CN201610825741 A CN 201610825741A CN 106421805 B CN106421805 B CN 106421805B
- Authority
- CN
- China
- Prior art keywords
- dextran
- oxygen
- hemoglobin
- sulfydryl
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of dextran cross-linked haematoglobin carriers of oxygen and the preparation method and application thereof; the preparation method; the following steps are included: the hydroxyl on Dextran 40 is oxidized to aldehyde radical with sodium metaperiodate; obtain activated dextran acid anhydride; it will be sulfhydryl protected on hemoglobin with 4-PDS; bovine hemoglobin after activated dextran acid anhydride and sulfydryl closing is crosslinked, and last sulfydryl deprotection obtains the dextran cross-linked haematoglobin carrier of oxygen.The P for the dextran cross-linked haematoglobin carrier of oxygen (Dex-Hb) that method of the invention obtains50It can effectively improve, taking-put oxygen ability is also improved, and realizes the intramolecular crosslinking of tetrameric hemoglobin body, to dramatically increase the tetramer stability of HBOCs, and then improves the physiological function of HBOCs.
Description
Technical field
The present invention relates to the blood substitute technical fields of hemoglobin-based oxygen carrier class, more particularly to a kind of dextran
Cross-linked haematoglobin carrier of oxygen and the preparation method and application thereof.
Background technique
Hemoglobin-based oxygen carrier (HBOCs) is to be wrapped up hemoglobin, modified or be crosslinked by chemical means to obtain
A substance, it is therefore intended that by package, modification or be crosslinked increase free hemoglobin molecular weight, reduce its renal toxicity,
And retain its ability for taking-putting oxygen.But it still has many problem in science for restricting its development and applying in HBOCs research urgently to solve
Certainly.Firstly, after chemical modification or crosslinking depolymerization easily occurs for hemoglobin, so that the tetramer legibility fusion of hemoglobin is
Dimer；Secondly, modification or crosslinking can also change haemoglobin molecule structure, so that it is taken-put oxygen ability and significantly change.Therefore,
Package, the reagent for modifying or being crosslinked selection and the site for acting on hemoglobin influence the performance of HBOCs very big.
Since the sulfydryl of Cys-93 (β) on hemoglobin side chain is group very active on hemoglobin.Therefore,
HBOCs majority is so that it is connected with macromolecular dressing agent by the sulfydryl of modified hemoglobin side chain cysteine.Have and grinds
Studying carefully proves to be modified when the sulfydryl on hemoglobin, those can be made to maintain T conformation to be converted to the energy of R Conformation Transition originally
As the energy for improving oxygen affinity, its oxygen affinity is caused to rise, it is difficult to oxygen is discharged to tissue, so that tissue cannot obtain
Enough oxygen exacerbates the anoxia-induced apoptosis of tissue.How preferably the stabilizing hemoglobin tetramer, improve it and take-put oxygen ability
It is the critical issue for needing to solve in HBOCs research.
Dextran crosslinking is a kind of technological means for preparing HBOCs, commonly uses sodium periodate oxidation.Sodium periodate oxidation
Method is that the hydroxyl on dextran is oxidized to aldehyde radical using sodium metaperiodate as oxidant, later with the ammonia of haemoglobin molecule
Base carries out cross-linking reaction.However, the sodium metaperiodate after oxidized dextran in reaction solution can not eliminate completely.Due to periodic acid
Sodium is a kind of strong oxidizer, and remaining sodium metaperiodate and the dextran containing multiple aldehyde radicals being oxidized can aoxidize blood red egg
Sulfydryl on white side chain causes dextran cross-linked haematoglobin (Dex-Hb) oxygen affinity so that ferroheme microenvironment changes
It is excessively high with power, the reduction of oxygen ability is taken-put, oxygen supply effect can not be played well, therefore cannot function as blood substitute use.
Summary of the invention
The purpose of the present invention is being directed to technological deficiency existing in the prior art, in a first aspect, providing one kind can stablize
Tetrameric hemoglobin body, and the dextran cross-linked haematoglobin carrier of oxygen for taking-putting oxygen ability can be improved, by dextran and blood
Lactoferrin is crosslinked to obtain, and includes two sulfydryls on each tetrameric hemoglobin body in the carrier of oxygen.
Second aspect, the present invention provides a kind of method for preparing the above-mentioned dextran cross-linked haematoglobin carrier of oxygen, by blood
It is mixed after sulfhydryl protected on Lactoferrin with activated dextran acid anhydride, crosslinks reaction；Sulfydryl is carried out after the completion of crosslinking again
Deprotection, obtains the dextran cross-linked haematoglobin carrier of oxygen.
The following steps are included:
1) hydroxyl on Dextran 40 is oxidized to aldehyde radical with sodium metaperiodate, obtains activated dextran acid anhydride；
2) will be sulfhydryl protected on hemoglobin with 4,4 '-two sulphur, two pyridine, the blood red egg after obtaining sulfydryl closing
It is white；
3) the activated dextran acid anhydride of step 1) is mixed with the hemoglobin after the closing of the sulfydryl of step 2), be crosslinked anti-
It answers, obtains the closed dextran cross-linked haematoglobin carrier of oxygen of sulfydryl；
4) the closed dextran cross-linked haematoglobin carrier of oxygen of the sulfydryl of step 3) is subjected to sulfydryl deprotection, obtains the right side
The sugared acid anhydride cross-linked haematoglobin carrier of oxygen is revolved, includes two sulfydryls on each tetrameric hemoglobin body in the carrier of oxygen.
Step 2) specifically:
It is dissolved after weighing 4,4 '-two sulphur, two pyridine with dehydrated alcohol, hemoglobin and 4 times of dehydrated alcohol bodies is added thereto
Long-pending buffer solution B, the hemoglobin after mixing in reacting under room temperature, after obtaining sulfydryl closing；Hemoglobin and 4,
The molar ratio of 4 '-two sulphur, two pyridine is 1:(4-8) (preferably 1:(4-6), most preferably 1:4).
The reaction time of step 2) is 3 hours；Preferably, the buffer solution B is 20mM phosphate buffer (pH7.4).
Step 1) specifically:
Dextran 40 is weighed respectively and sodium metaperiodate is dissolved in buffer solution A, so that Dextran 40 is final concentration of
2.5mg/ml, the final concentration of 10mM of sodium metaperiodate obtain reaction system, and room temperature is protected from light 90 minutes, by Dextran 40
On hydroxyl be oxidized to aldehyde radical；Ethylene glycol is added after reaction and stands 1-3h, terminates sodium periodate oxidation reaction, feed ratio is
3-6 μ l ethylene glycol is added in 1mg sodium metaperiodate；It is dialysed, is removed at room temperature with NaCl solution and buffer solution B respectively after reaction terminating
Remaining sodium metaperiodate and ethylene glycol (using the bag filter of 10kDa), obtain activated dextran acid anhydride；Preferably, the buffer solution A
For the Acetate-acetate buffer solution (pH5.8) of 20mM sodium acetate.
Step 3) specifically:
The activated dextran acid anhydride and cyano boron hydrogen that hemoglobin, step 1) after the sulfydryl that step 2) obtains is closed obtain
Change sodium powder end 1:(0.05-5 in mass ratio): (0.25-2.5) is uniformly mixed (preferably 1:(1-2): (0.5-1), most preferably 1:1:
0.5) it, is protected from light and is overnight crosslinked hemoglobin and dextran；Ultrafiltration is carried out with buffer solution B after fully reacting, is obtained
To the closed dextran cross-linked haematoglobin carrier of oxygen of sulfydryl.
Step 4) specifically:
Three (2- carboxyethyl) phosphonium salt hydrochlorates are weighed, as deprotection agent, three (2- carboxyethyl) phosphonium salts acid after using pure water to dissolve
Salt is 4 times of hemoglobin molal quantity, and the closed dextran cross-linked haematoglobin carrier of oxygen of sulfydryl obtained to step 3) is super
Filter, is deprotected closed sulfydryl；Continue to use buffer solution B ultrafiltration after fully reacting, obtains dextran and be crosslinked blood red egg
The white carrier of oxygen.
The third aspect, the present invention provide a kind of dextran cross-linked haematoglobin carrier of oxygen, are prepared by the above method
It arrives.
Fourth aspect, the present invention provide the above-mentioned dextran cross-linked haematoglobin carrier of oxygen answering in blood substitute
With the carrier of oxygen is applied in transfusion procedure (caused by wound, blood loss, anaemia, operation etc.), is partly or entirely substituted red
Oxygen function, partial pressure of oxygen P when oxygen saturation is 50% are taken/put to cells play50In 9.00mmHg or more.
Compared with prior art, the beneficial effects of the present invention are:
The present invention improves the method for dextran cross-linked haematoglobin, is preparing dextran cross-linked haematoglobin
Reversible protection HbC ys-93 (β) sulfydryl, keeps its not oxidized during the carrier of oxygen (Dex-Hb).As a result it confirms: this
The P for the dextran cross-linked haematoglobin carrier of oxygen (Dex-Hb) that the method for invention obtains50It can effectively improve, take-put oxygen
Ability is also improved.Since multiple aldehyde groups that dextran oxidation generates can be simultaneously and on four subunits of hemoglobin
Amino reaction, realize the intramolecular crosslinking of tetrameric hemoglobin body, to dramatically increase the tetramer stability of HBOCs, into
And improve the physiological function of HBOCs.
Detailed description of the invention
Fig. 1 (A) width indicates that 3 gel filtration chromatography figure of embodiment, (B) width indicate the experimental result of SDS-PAGE；
Fig. 2 show the oxygen dissociation curve figure of embodiment 3；
Fig. 3 (A) width indicates that the ferrihemoglobin content figure of embodiment 3, (B) width indicate gel filtration chromatography figure；
Fig. 4 show the extent of reaction figure of embodiment 3, embodiment 4, comparative example 1 and comparative example 2.
Specific embodiment
The preparation of buffer:
1. Acetate-acetate buffer solution (NaAC-HAC, pH5.8,20mM, hereinafter referred to as " buffer solution A ")
Anhydrous sodium acetate 1.64g is weighed, is dissolved in 900ml pure water, pH to 5.8 is adjusted with glacial acetic acid, is settled to pure water
1L to get.
2. phosphate buffer (PB, pH7.4,20mM, hereinafter referred to as " buffer solution B ")
4.8g anhydrous sodium dihydrogen phosphate (119.98) and 14.8g disodium hydrogen phosphate (358.14) are weighed, 4L is dissolved in
In pure water dissolve to get.
The method for preparing the dextran cross-linked haematoglobin carrier of oxygen of the present invention, comprising the following steps:
1) Dextran 40 is weighed respectively and sodium metaperiodate (weighing under the conditions of being protected from light) is dissolved in buffer solution A, is obtained anti-
System is answered, so that the final concentration of 2.5mg/ml of Dextran 40, the final concentration of 10mM of sodium metaperiodate, reaction system room temperature are kept away
Hydroxyl on Dextran 40 is oxidized to aldehyde radical by light reaction 90min, sodium metaperiodate.Second is added into the reaction system after oxidation
Glycol stands 1-3h, terminates sodium periodate oxidation reaction, and feed ratio is that 3-6 μ l ethylene glycol is added in 1mg sodium metaperiodate.It will terminate
The reaction system of oxidation is dialysed twice with the NaCl solution room temperature of 0.15M, each 1h, then is dialysed 1 time with buffer solution B room temperature, when
Between be 3h, remove remaining sodium metaperiodate and ethylene glycol (using the bag filter of 10kDa), obtain activated dextran acid anhydride.
2) be in molar ratio 4,4 '-two sulphur, two pyridine (4-PDS): bovine hemoglobin=(4-8): 1 feed ratio weighs 4-
PDS, with dehydrated alcohol dissolution 4-PDS (volume (mL) of dehydrated alcohol is after 20-30 times of 4-PDS mass (g), thereto plus
Enter buffer solution B (volume be dehydrated alcohol 4 times)), it adds bovine hemoglobin and is uniformly mixed the reaction for carrying out closing sulfydryl, room
Temperature reaction 2-5h, the bovine hemoglobin after obtaining sulfydryl closing.
3) the activated dextran acid anhydride and cyano that bovine hemoglobin, step 1) after closing the sulfydryl that step 2) obtains obtain
Sodium borohydride powder 1:(0.05-5 in mass ratio): (0.25-2.5) mixes (preferably 1:(1-2): (0.5-1), most preferably 1:1:
0.5) it, is protected from light overnight (8-12h), is obtained containing the closed dextran cross-linked haematoglobin carrier of oxygen of sulfydryl in 4 DEG C
Reaction solution.The reaction solution of step 3) is subjected to ultrafiltration with buffer solution B, sets flow velocity as 4.0ml/min, ultrafiltration 7-9h obtains mercapto
The closed dextran cross-linked haematoglobin carrier of oxygen of base.
4) be in molar ratio bovine hemoglobin: the feed ratio of three (2- carboxyethyl) phosphonium salt hydrochlorate (TCEPHCl)=1:4 claims
TCEPHCl is taken, after being dissolved with pure water, as deprotection agent, blood is crosslinked to the closed dextran of sulfydryl that step 3) obtains
The Lactoferrin carrier of oxygen continues ultrafiltration, releases the closing to sulfydryl, reacts 40min.Continue later with buffer solution B ultrafiltration 7-
8h obtains the dextran cross-linked haematoglobin carrier of oxygen of liquid.
5) sample, -80 DEG C of preservations are collected.
Below in conjunction with specific embodiment, the content of the present invention will be explained in more detail, and the present invention is further elaborated, but
These embodiments limit the invention absolutely not.
Embodiment:
A series of dextran cross-linked haematoglobin carriers of oxygen are prepared in aforementioned manners, only the parameter of preparation process
It slightly adjusts, remaining program is constant, and the parameter of preparation process is shown in Table 1.
1 present invention of table prepares the parameter of the method for the dextran cross-linked haematoglobin carrier of oxygen
Comparative example 1: by taking embodiment 3 as an example, the present invention is prepared into the dextran cross-linked haematoglobin carrier of oxygen of the present invention
Bovine hemoglobin, activated dextran acid anhydride and the mass ratio of sodium cyanoborohydride powder in method after the closing of step 3) sulfydryl are changed to
1: 0.01: 0.5, as a result other steps and parameter constant are shown in Fig. 4.As the result is shown: the cross-linking effect of embodiment 3 and embodiment 4 compared with
Good, remaining hemoglobin content is less, considers that economy principle can more save the original of cross-linking reaction when reaction is than being 1: 1: 0.5
Material；And responseless hemoglobin is more in comparative example 1, product purity is poor.
Comparative example 2: by taking embodiment 3 as an example, the present invention is prepared into the dextran cross-linked haematoglobin carrier of oxygen of the present invention
Bovine hemoglobin, activated dextran acid anhydride and the mass ratio of sodium cyanoborohydride powder in method after the closing of step 3) sulfydryl are changed to
1:0.5:0.1, other steps and parameter constant, are as a result shown in Fig. 4.As the result is shown: responseless hemoglobin is more, and product is pure
It spends poor.
Test one: SDS-PAGE (SDS- polyacrylamide gel electrophoresis) and gel filtration chromatography
By the SDS- polyacrylamide gel of the protein of page 1713 in " Molecular Cloning:A Laboratory guide " (third edition) volume two
Method in electrophoresis carries out SDS-PAGE experiment to embodiment 1-8.After preparing 12% separation gel and 5% concentration glue, electricity is installed
Electrophoretic buffer is added in swimming system；The dextran cross-linked haematoglobin oxygen carrier sample of 1-8 of the embodiment of the present invention is (blood red
Protein content is 35mg) with the sample-loading buffers (loading buffer) of 5 times of volumes (i.e.+20 μ l 5 of 5 μ l sample ×
Loading buffer) mixing；It is put into boiling water and heats 5min, be centrifuged, take 20 μ l supernatant loadings；Using Bole's electrophoresis apparatus, surely
120V 30min is pressed, sample is made to enter separation gel, pressure stabilizing 90V runs electrophoresis later；Dyeing, decoloration, record experimental result.
By the experimental method in Wang et al.Biochim Biophys Acta 2014,1844:1201-1207 to reality
Apply the experiment that a 1-8 carries out gel filtration chromatography.
By taking embodiment 3 as an example, in Fig. 1 (A) width indicate gel filtration chromatography as a result, (B) width indicate SDS-PAGE knot
Fruit.
It can be seen that hemoglobin (Hb) from the SDS-PAGE electrophoresis result of (B) width in Fig. 1 only to show at 16kDa
One band occurs without other bands.It is higher to demonstrate Hb purity, meets preparation and requires.Dextran cross-linked haematoglobin
The carrier of oxygen (Dex-Hb) only shows a band in 100kDa or more, illustrates that the purity of Dex-Hb is higher.And 97kDa with
Under, Dex-Hb does not have band appearance, illustrates that the molecular weight of Dex-Hb is greater than 97kDa, cross-linking reaction significantly increases hemoglobin
The molecular weight of molecule.
From Fig. 1 the gel filtration chromatography figure of (A) width can be seen that Hb occur one it is symmetrical unimodal, illustrate Hb's
Purity is higher, occurs without impurity.It can be concluded that (1) Dex-Hb only goes out from the appearance time and peak type of Dex-Hb
Showed one it is symmetrical unimodal, illustrate that Dex-Hb purity is higher, be free of other impurities.(2) appearance time of Dex-Hb is said earlier than Hb
The molecular weight of bright Dex-Hb is greater than Hb, and cross-linking reaction has successfully increased the molecular weight of haemoglobin molecule.
Other embodiments also have similar effect, no longer repeat one by one.
Experiment two: take-put oxygen ability
P by the dextran cross-linked haematoglobin carrier of oxygen (containing hemoglobin 6mg) of embodiment 1-8 with 4ml pH7.450
Buffer (P50Buffer: weighing 7.89g sodium chloride, and 6.89g TES and 0.373g potassium chloride is dissolved in ultrapure water, at 37 DEG C
PH=7.4 ± 0.02 is adjusted, osmotic pressure is 295 ± 10mOsm/kg, is settled to 1L, 4 DEG C save backup) it mixes, control reactant
The temperature of system is 37 DEG C, (by taking embodiment 3 as an example, sees the song in Fig. 2 with the oxygen dissociation curve of blood oxygen analysis instrument measurement reaction system
Line b) and P50(partial pressure of oxygen when oxygen saturation is 50%).The oxygen dissociation curve of hemoglobin (Hb) is obtained using same method
(see the curve a) and P in Fig. 250)。
P50Partial pressure of oxygen when be oxygen saturation being 50%, is to characterize hemoglobin to take-put the important indicator of oxygen ability.Fig. 2
Indicate that (i.e. the dextran cross-linked haematoglobin oxygen of embodiment 3 carries the product b being crosslinked by the method for inventive closure sulfydryl
Body) oxygen dissociation curve and P of the product a that are crosslinked with unclosed sulfydryl50Situation of change.Unclosed mercapto as can be seen from Figure 2
Dex-Hb (the P of product a) of base50It is too low, it is 4.61mmHg, P50It is too low to be unfavorable for providing oxygen to tissue.With unclosed sulfydryl
Dex-Hb (product a) is compared, and (product b) oxygen dissociation curve moves to right, and P by Dex-Hb obtained after closing sulfydryl50It increases to
9.86mmHg.Compared with the Dex-Hb of unclosed sulfydryl, the P of the Dex-Hb of sulfydryl is closed50It significantly improves, it was demonstrated that closing sulfydryl side
What method can effectively improve Dex-Hb takes-puts oxygen ability.
Other embodiments also have similar effect, no longer repeat one by one.
Experiment three: tetrameric hemoglobin body stability
According to Benesch RE, Benesch R, Yung S.Equations for the spectrophotometric
Analysis of hemoglobin mixtures.Anal Biochem, 1973,55 (1): the method in 245-248. is to this
The embodiment 1-8 of invention carries out ferrihemoglobin detection, specifically: PBS solution is prepared, 0.22 μm of membrane filtration is spare；Point
The dextran cross-linked haematoglobin carrier of oxygen (Dx40-Hb) and Hb that other Example 1-8 is obtained as sample be packed into 15ml from
In heart pipe, constant volume to 10ml guarantees the final concentration of 1.6mg/ml of hemoglobin；MgCl is separately added into sample2To final concentration
For 0.9M；1ml sample is taken respectively, surveys it in the absorbance of 540nm, 560nm, 576nm, 630nm, 700nm；By remaining sample
(it is not added with MgCl2Sample) be put into water-bath, 37 DEG C of water-baths, respectively in 1h, 2h, 3h, 4h, 6h, 7h, take 1ml solution, survey
Its absorbance in 540nm, 560nm, 576nm, 630nm, 700nm；0h, 1h, 2h, 3h, 4h, 6h, 7h are calculated with Spectrophotometry Method Using Three-wavelength
Ferrihemoglobin percentage composition；Mapping, by taking embodiment 3 as an example, is as a result shown in Fig. 3 (A).
Gel filtration chromatography experimentation (identical as one method of experiment): take Hb sample and Dex-Hb sample (blood red respectively
Protein content is 300 μ g) in 150 μ l PBS, magnesium chloride is added to final concentration 0.9M, 300 μ l of total system, 37 DEG C of reactions
150min crosses 0.45 μm of filter, takes 100 μ l loadings；Setting Detection wavelength is 280nm, and loading speed is 0.5mg/ml, is coagulated
As a result glue filtering chromatogram figure is shown in Fig. 3 (B) by taking embodiment 3 as an example.
Fig. 3 indicates influence of the closing sulfydryl to tetrameric hemoglobin body stability.MgCl2Hemoglobin can be promoted by four
Aggressiveness depolymerization becomes dimer, to easily aoxidize, when hemoglobin oxygen turns to ferrihemoglobin, loses in conjunction with oxygen
Function, that is, lose biological action, thus when preparing hemoglobin-based oxygen carrier require ferrihemoglobin content it is lower
Better.Fig. 3 (A) is shown in MgCl2Under effect, obviously aoxidizing occurs in Hb, variable quantity nearly 100% (curve a), and for Dex-
For Hb, MetHb changes of contents is little, and variable quantity is less than 30% (curve b), it was demonstrated that the Dex-Hb tetramer is much higher than Hb；It is bent
Line c and d essentially coincide the change for showing that the method for the present invention does not cause hemoglobin oxidation state in cross-linking process, therefore obtain
To Dex-Hb in no MgCl2In the case where, it is almost the same with the tetramer structure stability of hemoglobin.
Gel filtration chromatography as the result is shown Fig. 3 (B) in MgCl2Under the action of, Hb appearance time lag, and in elution volume
Occur two peaks (as shown by arrows in figure) before and after 20ml, illustrates that obvious depolymerization occurs in Hb；And Dex-Hb is in MgCl2Effect is lower out
Peak time is basically unchanged, and only presents unimodal, illustrates that its depolymerization is not obvious；The result confirm: closing sulfydryl Dex-Hb have compared with
High tetramer stability.
Other embodiments also have similar effect, no longer repeat one by one.
The above is only a preferred embodiment of the present invention, it is noted that for the common skill of the art
For art personnel, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications
Also the contents of the present invention be should be regarded as.
Claims (19)
1. a kind of method for preparing the dextran cross-linked haematoglobin carrier of oxygen, which is characterized in that the dextran is crosslinked blood
The Lactoferrin carrier of oxygen is crosslinked to obtain by dextran with hemoglobin, includes on each tetrameric hemoglobin body in the carrier of oxygen
Two sulfydryls will mix with activated dextran acid anhydride after sulfhydryl protected on hemoglobin, crosslink reaction；Crosslinking is completed
It carries out sulfydryl deprotection again afterwards, obtains the dextran cross-linked haematoglobin carrier of oxygen；
The activated dextran acid anhydride is that the hydroxyl on Dextran 40 is oxidized to aldehyde radical with sodium metaperiodate to obtain.
2. method according to claim 1, which comprises the following steps:
1) hydroxyl on Dextran 40 is oxidized to aldehyde radical with sodium metaperiodate, obtains activated dextran acid anhydride；
2) will be sulfhydryl protected on hemoglobin with 4,4 '-two sulphur, two pyridine, the hemoglobin after obtaining sulfydryl closing；
3) the activated dextran acid anhydride of step 1) is mixed with the hemoglobin after the closing of the sulfydryl of step 2), carries out cross-linking reaction,
Obtain the closed dextran cross-linked haematoglobin carrier of oxygen of sulfydryl；
4) the closed dextran cross-linked haematoglobin carrier of oxygen of the sulfydryl of step 3) is subjected to sulfydryl deprotection, obtains dextrose
The acid anhydride cross-linked haematoglobin carrier of oxygen includes two sulfydryls on each tetrameric hemoglobin body in the carrier of oxygen.
3. method according to claim 2, which is characterized in that step 2) specifically:
It is dissolved after weighing 4,4 '-two sulphur, two pyridine with dehydrated alcohol, hemoglobin and 4 times of dehydrated alcohol volumes is added thereto
Buffer solution B, the hemoglobin after mixing in reacting under room temperature, after obtaining sulfydryl closing；Hemoglobin and 4,4 '-two
The molar ratio of two pyridine of sulphur is 1:(4-8)；The buffer solution B is the phosphate buffer of 20mM, pH 7.4.
4. method according to claim 3, which is characterized in that the hemoglobin and 4, the molar ratio of 4 '-two sulphur, two pyridine
For 1:(4-6).
5. method according to claim 3, which is characterized in that the hemoglobin and 4, the molar ratio of 4 '-two sulphur, two pyridine
For 1:4.
6. method according to claim 4, which is characterized in that the reaction time of step 2) is 3 hours.
7. according to any the method for claim 2-6, which is characterized in that step 1) specifically:
Dextran 40 is weighed respectively and sodium metaperiodate is dissolved in buffer solution A, so that Dextran 40 is final concentration of
2.5mg/ml, the final concentration of 10mM of sodium metaperiodate obtain reaction system, and room temperature is protected from light 90 minutes, by Dextran 40
On hydroxyl be oxidized to aldehyde radical；Ethylene glycol is added after reaction and stands 1-3h, terminates sodium periodate oxidation reaction, feed ratio is
3-6 μ l ethylene glycol is added in 1mg sodium metaperiodate；It is dialysed, is removed at room temperature with NaCl solution and buffer solution B respectively after reaction terminating
Remaining sodium metaperiodate and ethylene glycol obtain activated dextran acid anhydride；The buffer solution A is sodium acetate-acetic acid of 20mM sodium acetate
Buffer, pH 5.8.
8. method according to claim 7, which is characterized in that step 3) specifically:
The activated dextran acid anhydride and sodium cyanoborohydride that hemoglobin, step 1) after the sulfydryl that step 2) obtains is closed obtain
Powder 1:(0.05-5 in mass ratio): (0.25-2.5) is uniformly mixed, and is protected from light and is overnight handed over hemoglobin and dextran
Connection gets up；Ultrafiltration is carried out with buffer solution B after fully reacting, obtains the closed dextran cross-linked haematoglobin carrier of oxygen of sulfydryl.
9. according to any the method for claim 2-6, which is characterized in that step 3) specifically:
The activated dextran acid anhydride and sodium cyanoborohydride that hemoglobin, step 1) after the sulfydryl that step 2) obtains is closed obtain
Powder 1:(0.05-5 in mass ratio): (0.25-2.5) is uniformly mixed, and is protected from light and is overnight handed over hemoglobin and dextran
Connection gets up；Ultrafiltration is carried out with buffer solution B after fully reacting, obtains the closed dextran cross-linked haematoglobin carrier of oxygen of sulfydryl.
10. method according to claim 9, which is characterized in that hemoglobin, activated dextran acid anhydride and cyanogen after sulfydryl closing
The mass ratio of base sodium borohydride powder is 1:(1-2): (0.5-1).
11. method according to claim 10, which is characterized in that sulfydryl closing after hemoglobin, activated dextran acid anhydride with
The mass ratio of sodium cyanoborohydride powder is 1:1:0.5.
12. according to any the method for claim 2-6, which is characterized in that step 4) specifically:
Three (2- carboxyethyl) phosphonium salt hydrochlorates are weighed, as deprotection agent after using pure water to dissolve, three (2- carboxyethyl) phosphonium salt hydrochlorates are
4 times of hemoglobin molal quantity, it is right to the closed dextran cross-linked haematoglobin carrier of oxygen ultrafiltration of sulfydryl that step 3) obtains
Closed sulfydryl is deprotected；Continue to use buffer solution B ultrafiltration after fully reacting, obtains dextran cross-linked haematoglobin oxygen load
Body.
13. method according to claim 7, which is characterized in that step 4) specifically:
Three (2- carboxyethyl) phosphonium salt hydrochlorates are weighed, as deprotection agent after using pure water to dissolve, three (2- carboxyethyl) phosphonium salt hydrochlorates are
4 times of hemoglobin molal quantity, it is right to the closed dextran cross-linked haematoglobin carrier of oxygen ultrafiltration of sulfydryl that step 3) obtains
Closed sulfydryl is deprotected；Continue to use buffer solution B ultrafiltration after fully reacting, obtains dextran cross-linked haematoglobin oxygen load
Body.
14. method according to claim 8, which is characterized in that step 4) specifically:
Three (2- carboxyethyl) phosphonium salt hydrochlorates are weighed, as deprotection agent after using pure water to dissolve, three (2- carboxyethyl) phosphonium salt hydrochlorates are
4 times of hemoglobin molal quantity, it is right to the closed dextran cross-linked haematoglobin carrier of oxygen ultrafiltration of sulfydryl that step 3) obtains
Closed sulfydryl is deprotected；Continue to use buffer solution B ultrafiltration after fully reacting, obtains dextran cross-linked haematoglobin oxygen load
Body.
15. method according to claim 9, which is characterized in that step 4) specifically:
Three (2- carboxyethyl) phosphonium salt hydrochlorates are weighed, as deprotection agent after using pure water to dissolve, three (2- carboxyethyl) phosphonium salt hydrochlorates are
4 times of hemoglobin molal quantity, it is right to the closed dextran cross-linked haematoglobin carrier of oxygen ultrafiltration of sulfydryl that step 3) obtains
Closed sulfydryl is deprotected；Continue to use buffer solution B ultrafiltration after fully reacting, obtains dextran cross-linked haematoglobin oxygen load
Body.
16. method according to claim 10, which is characterized in that step 4) specifically:
Three (2- carboxyethyl) phosphonium salt hydrochlorates are weighed, as deprotection agent after using pure water to dissolve, three (2- carboxyethyl) phosphonium salt hydrochlorates are
4 times of hemoglobin molal quantity, it is right to the closed dextran cross-linked haematoglobin carrier of oxygen ultrafiltration of sulfydryl that step 3) obtains
Closed sulfydryl is deprotected；Continue to use buffer solution B ultrafiltration after fully reacting, obtains dextran cross-linked haematoglobin oxygen load
Body.
17. a kind of dextran cross-linked haematoglobin carrier of oxygen, which is characterized in that be by any the method for claim 1-16
It is prepared.
18. the dextran cross-linked haematoglobin carrier of oxygen described in claim 17 is preparing the application in blood substitute, by institute
It states the carrier of oxygen to apply in transfusion procedure, partly or entirely substitutes red blood cell performance and take/put oxygen function, oxygen saturation 50%
When partial pressure of oxygen P50In 9.00mmHg or more.
19. 8 application according to claim 1, which is characterized in that the transfusion procedure is by wound, blood loss, anaemia, operation
It is caused.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610825741.2A CN106421805B (en) | 2016-09-14 | 2016-09-14 | A kind of dextran cross-linked haematoglobin carrier of oxygen and the preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610825741.2A CN106421805B (en) | 2016-09-14 | 2016-09-14 | A kind of dextran cross-linked haematoglobin carrier of oxygen and the preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106421805A CN106421805A (en) | 2017-02-22 |
| CN106421805B true CN106421805B (en) | 2019-06-04 |
Family
ID=58168470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610825741.2A Active CN106421805B (en) | 2016-09-14 | 2016-09-14 | A kind of dextran cross-linked haematoglobin carrier of oxygen and the preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106421805B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112129946A (en) * | 2020-08-16 | 2020-12-25 | 陆修委 | Preparation method and application of sugar-free chain type inert protein sealant |
| CN114617957B (en) * | 2022-03-10 | 2024-01-16 | 中国人民解放军军事科学院军事医学研究院 | Hydroxyethyl starch hemoglobin conjugate, and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5449759A (en) * | 1987-05-16 | 1995-09-12 | Somatogen, Inc. | Hemoglobins with intersubunit desulfide bonds |
| CN102405051A (en) * | 2010-05-27 | 2012-04-04 | 黄炳镠 | High-temperature stable oxygen-carrier-containing pharmaceutical composition |
| CN104379160A (en) * | 2012-03-29 | 2015-02-25 | 桑加特公司 | Diaspirin crosslinked pegylated hemoglobin |
-
2016
- 2016-09-14 CN CN201610825741.2A patent/CN106421805B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5449759A (en) * | 1987-05-16 | 1995-09-12 | Somatogen, Inc. | Hemoglobins with intersubunit desulfide bonds |
| CN102405051A (en) * | 2010-05-27 | 2012-04-04 | 黄炳镠 | High-temperature stable oxygen-carrier-containing pharmaceutical composition |
| CN104379160A (en) * | 2012-03-29 | 2015-02-25 | 桑加特公司 | Diaspirin crosslinked pegylated hemoglobin |
Non-Patent Citations (3)
| Title |
|---|
| Binding of 21 Thiol Reagents to Human Hemoglobin in Solution and in Intact Cells;Marie Claude GAREL et al.;《Eur. J. Biochem.》;19821231;第123卷;第513-519页 * |
| Bohr effect of human hemoglobin A: Magnitude of negative contributions determined by the equilibrium between two tertiary structures;Kehinde O. Okonjo et al.;《Biophysical Chemistry》;20140422;第41-49页 * |
| MODIFICATION OF HUMAN H E M O G L O B I N BY COVALENT ASSOCIATION WITH SOLUBLE DEXTRAN;EDITH DELLACHERIE et al.;《Biochimica et Biophvsica Acta》;19831231;第749卷;第106-114页，尤其是摘要 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106421805A (en) | 2017-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4674289B2 (en) | Hemoglobin-polysaccharide conjugate | |
| Manjula et al. | Conjugation of multiple copies of polyethylene glycol to hemoglobin facilitated through thiolation: influence on hemoglobin structure and function | |
| US6083909A (en) | Haemoglobin-hydroxyethyl starch conjugates as oxygen carriers | |
| US5194590A (en) | Acellular red blood cell substitute | |
| US20040029780A1 (en) | Synthetic oxygen transport made from cross-linked modified human or porcine haemoglobin with improved properties, method for a preparation thereof from purified material and use thereof | |
| EP0259197A1 (en) | Macromolecular conjugates of hemoglobin, process for preparing them and their uses | |
| CN106421805B (en) | A kind of dextran cross-linked haematoglobin carrier of oxygen and the preparation method and application thereof | |
| US20040023851A1 (en) | Method for the porduction of artificial oxygen carriers from covalently cross linking haemoglobin with improved functional properties of haemoglobin by cross- linking in the presence of chemically non- reacting effectors of the oxygen affinity of the haemoglobin | |
| Zhang et al. | Site-selective glycosylation of hemoglobin on Cys β93 | |
| Hu et al. | A solid phase adsorption method for preparation of bovine serum albumin–bovine hemoglobin conjugate | |
| Marini et al. | Reexamination of the polymerization of pyridoxylated hemoglobin with glutaraldehyde | |
| Haest et al. | Formation of disulfide bonds between glutathione and membrane SH groups in human erythrocytes | |
| Allis et al. | Acid denaturation of carbonylhemoglobin. Protein unfolding without heme detachment | |
| JPH10316579A (en) | Hemoglobin having protecting ligand at oxygen-binding site as artificial oxygen carrier for being directly used for biological medical treatment and its production | |
| MacDonald et al. | [19] Hemoglobin polymerization | |
| ES2399835T3 (en) | Hemoglobin-antioxidant conjugates | |
| CA2791122A1 (en) | Methods for preparing peg-hemoglobin conjugates using reduced reactant ratios | |
| Iwasaki et al. | Hemoglobin-inulin conjugate as an oxygen carrying blood substitute | |
| Manning | [14] Preparation of hemoglobin carbamylated at specific NH2-terminal residues | |
| CN115317595A (en) | Pegylated bovine hemoglobin oxygen carrier and preparation method and application thereof | |
| CN114617957B (en) | Hydroxyethyl starch hemoglobin conjugate, and preparation method and application thereof | |
| Razynska et al. | Zero-link polymerization: a new class of polymeric hemoglobins | |
| WO1992008478A1 (en) | Method of enhancing long-term storage stability of hemoglobin products | |
| WO2004089404A1 (en) | Hemoglobin conjugate and the preparation method and its use | |
| US20120059153A1 (en) | Methods for preparing stable deoxygenated peg-hemoglobin conjugate solutions comprising an antioxidant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhao Lian Inventor after: Wang Ying Inventor after: Zhou Hong Inventor after: Hu Tao Inventor after: Wang Quan Inventor after: Zhang Jun Inventor after: Zhao Jingxiang Inventor before: Zhou Hong Inventor before: Zhao Lian Inventor before: Wang Ying Inventor before: Hu Tao Inventor before: Wang Quan Inventor before: Zhang Jun Inventor before: Zhao Jingxiang |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210628 Address after: 100850 No. 27 Taiping Road, Beijing, Haidian District Patentee after: INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES PLA CHINA Address before: 100850 No. 27 Taiping Road, Beijing, Haidian District Patentee before: Institute of Field Blood Transfusion, Chinese Academy of Military Medical Sciences |
|
| TR01 | Transfer of patent right |